[an error occurred while processing this directive]
Reviews

Advances in genetic studies of Charcot-Marie-Tooth disease type 4 (CMT4)

Expand
  • 1. School of Medicine, Shanghai Jiao Tong University Shanghai 200025, China;
    2. Department of Medical Genetics, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2014-11-25

  Revised date: 2015-03-25

  Online published: 2015-06-20

Abstract

The Charcot-Marie-Tooth disease (CMT) is one of the most common human inherited peripheral neuropathies. The most common pattern of inheritance is autosomal dominant, with less often occurrence autosomal recessive and X-linked dominant/recessive inheritance. CMT is generally divided into three forms: demyelinating forms (CMT1), axonal forms (CMT2) and intermediate forms (DI-CMT). The autosomal recessive form (AR-CMT1 or CMT4) is accompanied by progressive distal muscle weakness and atrophy of the limbs, pes cavus and claw-like hands. In addition, CMT4 is also characterized by early onset, rapid progression, and varying degrees of sensory loss and spinal deformities (e.g. scoliosis). Recently, 11 subtypes of CMT4 have been identified. Some of these subtypes were clear in pathogenic mechanisms, some had founder mutation, but some still had limited clinical description and mutation analysis. In this review, we summarize the latest research progresses of CMT4, including genotypes and phenotypes, pathogenic mechanisms and mouse models.

Cite this article

Ye Xu, Jiaying Zhang, Boyu Yang, Zhihong He, Muchen Zhang, Zhen Yu, Mingmin Gu . Advances in genetic studies of Charcot-Marie-Tooth disease type 4 (CMT4)[J]. Hereditas(Beijing), 2015 , 37(6) : 501 -509 . DOI: 10.16288/j.yczz.14-412

References

[1] Lupski JR, Reid JG, Gonzaga-Jauregui C, Rio Deiros D, Chen DC, Nazareth L, Bainbridge M, Dinh H, Jing C, Wheeler DA, McGuire AL, Zhang F, Stankiewicz P, Halperin JJ, Yang C, Gehman C, Guo D, Irikat RK, Tom W, Fantin NJ, Muzny DM, Gibbs RA. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med , 2010, 362(13): 1181-1191.
[2] Rossor AM, Polke JM, Houlden H, Reilly MM. Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol , 2013, 9(10): 562-571.
[3] Xu WY, Gu MM, Sun LH, Guo WT, Zhu HB, Ma JF, Yuan WT, Kuang Y, Ji BJ, Wu XL, Chen Y, Zhang HX, Sun FT, Huang W, Huang L, Chen SD, Wang ZG. A nonsense mutation in DHTKD1 causes Charcot-Marie-Tooth disease type 2 in a large Chinese pedigree. Am J Hum Genet , 2012, 91(6): 1088-1094.
[4] Claeys KG, Lammens M, Senderek J, Weis J. Autosomal recessive demyelinating or axonal Charcot-Marie-Tooth neuropathy. In: Vallat JM, Director JW. Peripheral nerve disorders: pathology and genetics. UK: The International Society of Neuropathology, 2014: 85-101.
[5] Baxter RV, Ben Othmane K, Rochelle JM, Stajich JE, Hulette C, Dew-Knight S, Hentati F, Ben Hamida M, Bel S, Stenger JE, Gilbert JR, Pericak-Vance MA, Vance JM. Ganglioside-induced differentiation-associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21. Nat Genet , 2002, 30(1): 21-22.
[6] Niemann A, Ruegg M, La Padula V, Schenone A, Suter U. Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network: new implications for Charcot-Marie-Tooth disease. J Cell Biol , 2005, 170(7): 1067-1078.
[7] Pedrola L, Espert A, Wu XY, Claramunt R, Shy ME, Palau F. GDAP1, the protein causing Charcot-Marie-Tooth disease type 4A, is expressed in neurons and is associated with mitochondria. Hum Mol Genet , 2005, 14(8): 1087-1094.
[8] Niemann A, Huber N, Wagner KM, Somandin C, Horn M, Lebrun-Julien F, Angst B, Pereira JA, Halfter H, Welzl H, Feltri ML, Young P, Wessig C, Toyka KV, Suter U. The Gdap1 knockout mouse mechanistically links redox control to Charcot-Marie-Tooth disease. Brain , 2014, 137(Pt 3): 668-682.
[9] Noack R, Frede S, Albrecht P, Henke N, Pfeiffer A, Knoll K, Dehmel T, Meyer Zu Hörste G, Stettner M, Kieseier BC, Summer H, Golz S, Kochanski A, Wiedau-Pazos M, Arnold S, Lewerenz J, Methner A. Charcot-Marie-Tooth disease CMT4A: GDAP1 increases cellular glutathione and the mitochondrial membrane potential. Hum Mol Genet , 2012, 21(1): 150-162.
[10] Tazir M, Bellatache M, Nouioua S, Vallat JM. Autosomal recessive Charcot-Marie-Tooth disease: from genes to phenotypes. J Peripher Nerv Syst , 2013, 18(2): 113-129.
[11] Bolino A, Bolis A, Previtali SC, Dina G, Bussini S, Dati G, Amadio S, Del Carro U, Mruk DD, Feltri ML, Cheng CY, Quattrini A, Wrabetz L. Disruption of Mtmr2 produces CMT4B1-like neuropathy with myelin outfolding and impaired spermatogenesis. J Cell Biol , 2004, 167(4): 711-721.
[12] Berger P, Berger I, Schaffitzel C, Tersar K, Volkmer B, Suter U. Multi-level regulation of myotubularin-related protein-2 phosphatase activity by myotubularin-related protein-13/set-binding factor-2. Hum Mol Genet , 2006, 15(4): 569-579.
[13] Robinson FL, Dixon JE. The phosphoinositide-3-phosphatase MTMR2 associates with MTMR13, a membrane-associated pseudophosphatase also mutated in type 4B Charcot-Marie-Tooth disease. J Biol Chem , 2005, 280(36): 31699-316707.
[14] Tersar K, Boentert M, Berger P, Bonneick S, Wessig C, Toyka KV, Young P, Suter U. Mtmr13/Sbf2-deficient mice: an animal model for CMT4B2. Hum Mol Genet , 2007, 16(24): 2991-3001.
[15] Robinson FL, Niesman IR, Beiswenger KK, Dixon JE. Loss of the inactive myotubularin-related phosphatase Mtmr13 leads to a Charcot-Marie-Tooth 4B2-like peripheral neuropathy in mice. Proc Natl Acad Sci USA , 2008, 105(12): 4916-4921.
[16] Ng AA, Logan AM, Schmidt EJ, Robinson FL. The CMT4B disease-causing phosphatases Mt
Outlines

/